How to Ensure Safety Factors in the Development of Artificial Heart: Verified by the Usage of ”Modeling and Simulation” Technology

  • Mitsuo Umezu
Conference paper

DOI: 10.1007/978-3-540-74771-0_10

Part of the Lecture Notes in Computer Science book series (LNCS, volume 4689)
Cite this paper as:
Umezu M. (2007) How to Ensure Safety Factors in the Development of Artificial Heart: Verified by the Usage of ”Modeling and Simulation” Technology. In: Li K., Li X., Irwin G.W., He G. (eds) Life System Modeling and Simulation. LSMS 2007. Lecture Notes in Computer Science, vol 4689. Springer, Berlin, Heidelberg

Abstract

The author has involved in two types of clinically available artificial hearts in Japan for these 30 years. Firstly, Toyobo auxiliary pulsatile ventricular assist pump was commercialized in 1991 and over 700 clinical cases are reported in Japanese market. Secondly, an implantable non-pulsatile ventricular assist pump (EVAHEART, Sunmedical Tech. Res. Co.) has been implanted into 11 patients in Japan. The author has been establishing a methodology to eliminate considerable risk factors through a development of hydrodynamic performance test, durability test and biocompatibility test. These in vitro tests are all effective to ensure a safety of the system and also in vitro tests have a contribution to reduce a number of animal experiments.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Mitsuo Umezu
    • 1
  1. 1.Integrative Bioscience and Biomedical Engineering, Graduate School of Waseda University, #58-322 3-4-1 Ohkubo, Shinjuku, Tokyo, 169-8555Japan

Personalised recommendations